Search academic texts

Information × Registration Number 0215U006018, 0112U001098 , R & D reports Title To study the role of endogenous peptide apelin in the development of heart lesions in essential hypertension patients with and without type 2 diabetes. popup.stage_title Head S. Koval, Registration Date 23-01-2015 Organization Government institution "L.T. Malaya Therapy Institute National Academy of Medical Sciences of Ukraine" popup.description2 It was found, that in patients with essential hypertension regardless of the presence or absence of diabetes development of pathological reorganization of the left ventricle of the heart can be predicted by mathematical modeling using apelin levels in the blood. It was established that lowering apelin levels in patients with essential hypertension as Type 2 diabetes, and without it is associated with the development of these patients pathological remodeling. The increasing production apelin in patients with essential hypertension as Type 2 diabetes, and without it, by the combined treatment with angiotensin-receptor blockers (ARBs) and calcium antagonist olmesartan lerkanidypin, lipid-lowering therapy with atorvastatin and antidiabetic metformin therapy (if presence of diabetes). Appointment in patients with essential hypertension and type DM2 without ACEI ramipril instead ARB olmesartan (compared to the aforementioned therapy) did not lead to any significant alteration apelinu levels in the blood. Detected in patients with essential hypertension and type 2 diabetes without increasing blood levels apelin after combined treatment using ARB olmesartan correlated with the degree of reduction in diastolic blood pressure of patients. It is shown that the antihypertensive effect of olmesartan largely be due to the ability of this group of drugs increase production of the peptide. Taking into consideration vazodilative, antiremodeling, antiatherogenic and antidiabetic properties of apelin, increasing its production reduces the risk of heart disease and improve cardiovascular prognosis of patients with essential hypertension as type 2 diabetes, and without it. Product Description popup.authors Висоцька О.В. Грідасова Л.М. Гудков С.М. Зоренко Н.В. Конькова В.С. Корнійчук І.А. Мазій В.В. Милославський Д.К. Остапюк О.С. Старченко Т.Г. Страшненко Г.М. Шуть І.В. Юшко К.О. popup.nrat_date 2020-04-02 Close